{
  "source": "PA-Med-Nec-Palynziq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2150-8\nProgram Prior Authorization/Medical Necessity\nMedication Palynziq™ (pegvaliase-pqpz)\nP&T Approval Date 9/2018, 7/2019, 7/2020, 6/2021, 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nPalynziq is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine\nconcentrations in adult patients with phenylketonuria who have uncontrolled blood phenylalanine\nconcentrations greater than 600 micromol/L on existing management.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Palynziq will be approved based on all of the following criteria:\na. Diagnosis of phenylketonuria (PKU)\n-AND-\nb. Patient is actively on a phenylalanine-restricted diet\n-AND-\nc. One of the following:\n(1) Patient has a contraindication to saptropterin (list reason)\n-OR-\n(2) History of failure or intolerance to sapropterin therapy (document date of trial and\nlist reason for therapeutic failure or intolerance) as determined by a one- to four-\nweek trial of sapropterin\n-AND-\nd. Physician attestation that the patient will not be receiving Palynziq in combination with\nsapropterin dihydrochloride\n-AND-\ne. Submission of medical records (e.g., chart notes, laboratory values) documenting that the\npatient has a blood phenylalanine concentration greater than 600 micromol/L\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services Inc.\n1\nB. Reauthorization\n1. Palynziq will be approved based on all of the following criteria:\na. Patient is actively on a phenylalanine-restricted diet\n-AND-\nb. One of the following:\n(1) Submission of medical records (e.g., chart notes, laboratory values) documenting that\nthe patient has a blood phenylalanine concentration less than 600 micromol/L\n-OR-\n(2) Submission of medical records (e.g., chart notes, laboratory values) documenting\nthat the patient has achieved a 20% reduction in blood phenylalanine concentration\nfrom pre-treatment baseline\n-OR-\n(3) P",
    "bmission of medical records (e.g., chart notes, laboratory values) documenting\nthat the patient has achieved a 20% reduction in blood phenylalanine concentration\nfrom pre-treatment baseline\n-OR-\n(3) Patient is in initial titration/maintenance phase of dosing regimen and dose is being\ntitrated based on blood phenylalanine concentration response up to maximum labeled\ndosage of 60 mg once daily\n-AND-\nc. Submission of medical records (e.g., chart notes, laboratory values) documenting that the\npatient is not receiving Palynziq in combination with sapropterin dihydrochloride\n[Prescription claim history that does not show any concomitant sapropterin\ndihydrochloride claim within 60 days of reauthorization request may be used as\ndocumentation.]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may also be in place.\n© 2024 UnitedHealthcare Services Inc.\n2\n4. References:\n1. Palynziq [package insert], Novato, CA: BioMarin Pharmaceutical Inc.; November 2020.\n2. Vockley et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline.\nAmerican College of Medical Genetics and Genomics Practice Guidelines. Genetics in Medicine\n2014;16 (2):188-200.\n3. Hydery T, Coppenrath VA. A Comprehensive Review of Pegvaliase, an Enzyme Substitution\nTherapy for the Treatment of Phenylketonuria. Drug Target Insights.\n2019;13:1177392819857089. Published 2019 Jun 21.\nProgram Prior Authorization/Medical Necessity - Palynziq (pegvaliase-pqpz)\nChange Control\n9/201",
    "the Treatment of Phenylketonuria. Drug Target Insights.\n2019;13:1177392819857089. Published 2019 Jun 21.\nProgram Prior Authorization/Medical Necessity - Palynziq (pegvaliase-pqpz)\nChange Control\n9/2018 New program\n7/2019 Annual review with no change to coverage criteria.\n7/2020 Annual review with no change to coverage criteria.\n6/2021 Added history of failure, contraindication, or intolerance to sapropterin\ndihydrochloride to criteria. Updated titration criteria in re-authorization.\nUpdated reference.\n7/2021 Updated contraindication, failure, intolerance criteria.\n7/2022 Annual review with no change to coverage criteria.\n7/2023 Annual review with no change to coverage criteria.\n7/2024 Annual review. Updated authorization durations to 12 months. Updated\nreferences.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}